The kynurenine pathway represents a critical metabolic axis linking tryptophan catabolism to neuroinflammation and neurodegeneration. This pathway generates several neuroactive metabolites—including kynurenic acid (KYNA) and quinolinic acid (QA)—that have opposing effects on neuronal health. Therapeutic modulation of this pathway has emerged as a promising strategy for treating neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), corticobasal degeneration (CBS), progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).
The therapeutic rationale centers on reducing neurotoxic metabolites (particularly quinolinic acid) while enhancing neuroprotective ones (kynurenic acid), or directly inhibiting rate-limiting enzymes like indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO).
Indoleamine 2,3-dioxygenase (IDO) and Tryptophan 2,3-dioxygenase (TDO) catalyze the first and rate-limiting steps in kynurenine pathway activation. Overexpression of these enzymes in neurodegenerative conditions leads to:
Drug candidates in development:
| Compound | Target | Stage | Company | Indication |
|---|---|---|---|---|
| Eoselodentib (LYNZE-LYM) | IDO1/TDO | Preclinical | Lynzyme | AD, PD |
| PF-06840003 | IDO1 | Phase I (terminated) | Pfizer | Oncology |
| BMS-986205 | IDO1 | Phase II | Bristol Myers | Oncology |
Clinical evidence:
KMO converts kynurenine to 3-hydroxykynurenine, which subsequently forms quinolinic acid—a potent NMDA receptor agonist and oxidative stress generator. KMO inhibition shifts metabolism toward kynurenic acid production.
Key compounds:
| Compound | Properties | Status | Evidence |
|---|---|---|---|
| JNJ-54178610 | Brain-penetrant KMO inhibitor | Preclinical | Reduced QA in CSF of PD patients |
| KMO inhibitor (UCB-61163) | Selective, brain-penetrant | Preclinical | Neuroprotection in HD models |
| Nicotinylalanine | Non-selective KMO inhibitor | Research | Proof-of-concept |
Advantages of brain-penetrant KMO inhibitors:
Kynurenic acid acts as an endogenous NMDA receptor antagonist, providing neuroprotection against excitotoxicity. However, KYNA poorly crosses the blood-brain barrier, limiting therapeutic utility.
Strategies under investigation:
| Approach | Compound | Evidence |
|---|---|---|
| KMO inhibition | JNJ-54178610 | Shifts toward KYNA production |
| Kynurenine administration | L-kynurenine | CSF KYNA increase in Phase I |
| Direct KYNA analogs | KYN-210, Br-KYN | Blood-brain barrier penetration |
| Gene therapy | KAT-II upregulation | Research stage |
Quinolinic acid (QA) is a neurotoxic metabolite that:
Therapeutic approaches:
| Strategy | Compound | Mechanism |
|---|---|---|
| KMO inhibition | Various | Block QA synthesis |
| QA antibodies | None approved | Neutralize circulating QA |
| Antioxidants | CoQ10, vitamin E | Protect against QA-induced ROS |
| NMDA antagonists | Memantine | Block QA receptor effects |
Pathology:
Clinical trials: None yet, but preclinical evidence supports:
Therapeutic potential: High — multiple pathway components dysregulated
Pathology:
Clinical data:
Therapeutic potential: High — neuroinflammation is central to PD pathogenesis
Pathology:
Therapeutic potential: Moderate — indirect evidence suggests benefit
Pathology:
Clinical trials:
Therapeutic potential: Very high — QA is dramatically elevated
Pathology:
Therapeutic potential: Moderate — shares neuroinflammatory features with AD/PD
Pathology:
Clinical trials:
Therapeutic potential: Highest — clearest genetic and biochemical rationale
| Trial ID | Compound | Phase | Disease | Status | Outcome |
|---|---|---|---|---|---|
| NCT02497114 | KMO inhibitor | I | HD | Completed | Reduced 3-HK in CSF |
| NCT03818386 | IDO1 inhibitor | I/II | AD | Terminated | No efficacy |
| NCT04185238 | L-kynurenine | I | PD | Completed | Increased CSF KYNA |